Cardiovascular risk in HIV-infected individuals: A comparison of three risk prediction algorithms

Boccara, 2008, Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors, AIDS, 22, S19, 10.1097/01.aids.0000327512.76126.6e Palella, 2011, Cardiovascular disease in HIV infection, Curr Opin HIV AIDS, 6, 266, 10.1097/COH.0b013e328347876c Bavinger, 2013, Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review, PLOS ONE, 8, e59551, 10.1371/journal.pone.0059551 INSA, 2017 DGS, 2016 Escárcega, 2014, Cardiovascular disease in patients with chronic human immunodeficiency virus infection, Int J Cardiol, 175, 1, 10.1016/j.ijcard.2014.04.155 Islam, 2012, Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis, HIV Med, 13, 453 Kamin, 2005, Cardiovascular disease in HIV-positive patients, AIDS, 19, 641, 10.1097/01.aids.0000166087.08822.bc Triant, 2013, Cardiovascular disease and HIV infection, Curr HIV/AIDS Rep, 10, 199, 10.1007/s11904-013-0168-6 Lake, 2011, Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study, AIDS Care, 23, 929, 10.1080/09540121.2010.543885 Shahbaz, 2015, Cardiovascular disease in human immunodeficiency virus infected patients: a true or perceived risk?, World J Cardiol, 7, 633, 10.4330/wjc.v7.i10.633 Hemkens, 2014, HIV infection and cardiovascular disease, Eur Heart J, 35, 1373, 10.1093/eurheartj/eht528 Fedele, 2011, Cardiovascular risk factors and HIV disease, AIDS Rev, 13, 119 De Socio, 2008, Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study, J Infect, 57, 33, 10.1016/j.jinf.2008.03.007 Reinsch, 2012, Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study, Eur J Prevent Cardiol, 19, 267, 10.1177/1741826711398431 Shahmanesh, 2016, The cardiovascular risk management for people living with HIV in Europe: how well are we doing?, AIDS, 30, 2505, 10.1097/QAD.0000000000001207 Mankal, 2014, From wasting to obesity, changes in nutritional concerns in HIV/AIDS, Endocrinol Metab Clin N Am, 43, 647, 10.1016/j.ecl.2014.05.004 Willig, 2014, Metabolic consequences of HIV: pathogenic insights, Curr HIV/AIDS Rep, 11, 35, 10.1007/s11904-013-0191-7 Worm, 2011, The metabolic syndrome in HIV. Best practice & research, Clin Endocrinol Metab, 25, 479 Jarrett, 2013, Metabolic syndrome predicts all-cause mortality in persons with human immunodeficiency virus, AIDS Pat Care STDs, 27, 266, 10.1089/apc.2012.0402 Tate, 2012, HIV infection and obesity: where did all the wasting go?, Antivir Therapy, 17, 1281, 10.3851/IMP2348 Crum-Cianflone, 2008, Obesity among patients with HIV: the latest epidemic, AIDS Pat Care STDs, 22, 925, 10.1089/apc.2008.0082 Lake, 2013, Metabolic disease in HIV infection, Lancet Infect Dis, 13, 964, 10.1016/S1473-3099(13)70271-8 Kim, 2012, Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering, J Acquir Immune Defic Syndr, 61, 600, 10.1097/QAI.0b013e31827303d5 Piepoli, 2016, Eur Heart J, 37, 2315, 10.1093/eurheartj/ehw106 Friis-Moller, 2003, Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study, AIDS, 17, 1179, 10.1097/00002030-200305230-00010 Cooney, 2010, Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference?. Can we see the future?, Circulation, 122, 300, 10.1161/CIRCULATIONAHA.109.852756 Authors/Task Force, 2016, Eur J Prevent Cardiol, 23, NP1, 10.1177/2047487316653709 Ladapo, 2017, Disparities in the quality of cardiovascular care between HIV-infected versus HIV-uninfected adults in the United States: a cross-sectional study, J Am Heart Assoc, 6, 10.1161/JAHA.117.007107 D’Agostino, 2012, Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population, J Infect Dis, 205, S362, 10.1093/infdis/jis196 De Wit, 2018, European AIDS Clinical Society Second Standard of Care Meeting Brussels 16-17 November 2016: a summary, HIV Med, 19, 77, 10.1111/hiv.12559 Friis-Moller, 2010, Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study, Eur J Cardiovasc Prev Rehabilit: Off J Eur Soc Cardiol Working Groups Epidemiol Prevent Cardiac Rehabilit Exerc Physiol, 17, 491, 10.1097/HJR.0b013e328336a150 1995, x, 452 Alberti, 2009, Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644 Landis, 1977, The measurement of observer agreement for categorical data, Biometrics, 33, 159, 10.2307/2529310 Signorini, 2012, What should we know about metabolic syndrome and lipodystrophy in AIDS?, Rev Assoc Med Brasil, 58, 70, 10.1016/S0104-4230(12)70157-4 Smith, 2004, Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population, HIV Med, 5, 88, 10.1111/j.1468-1293.2004.00191.x Nery, 2013, Cardiovascular risk assessment: a comparison of the Framingham PROCAM, and DAD equations in HIV-infected persons, ScientificWorldJournal, 2013, 969281, 10.1155/2013/969281 Knobel, 2007, Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham SCORE, and PROCAM), AIDS Pat Care STDs, 21, 452, 10.1089/apc.2006.0165 Glass, 2006, Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study, HIV Med, 7, 404, 10.1111/j.1468-1293.2006.00400.x DGS, 2017 Masia, 2012, Cardiovascular risk in human immunodeficiency virus-infected patients in Spain CoRIS cohort, 2011, Enferm Infec Microbiol Clin, 30, 517, 10.1016/j.eimc.2012.02.014 Hsue, 2012, Immunologic basis of cardiovascular disease in HIV-infected adults, J Infect Dis, 205, S375, 10.1093/infdis/jis200 Croxford, 2017, Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort, Lancet Publ Health, 2, e35, 10.1016/S2468-2667(16)30020-2 Maloberti, 2013, Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function, Metab Syndr Rel Disord, 11, 403, 10.1089/met.2013.0008 Raposo, 2017, The prevalence of the metabolic syndrome in Portugal: the PORMETS study, BMC Publ Health, 17, 555, 10.1186/s12889-017-4471-9 Aboud, 2010, Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study, Int J Clin Pract, 64, 1252, 10.1111/j.1742-1241.2010.02424.x Lichtenstein, 2010, Low CD4+T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study, Clin infect Dis: Off Publ Infect Dis Soc Am, 51, 435, 10.1086/655144 Grinspoon, 2005, Cardiovascular risk and body-fat abnormalities in HIV-infected adults, N Engl J Med, 352, 48, 10.1056/NEJMra041811 Hester, 2012, HIV medications: an update and review of metabolic complications, Nutr Clin Pract: Off Publ Am Soc Parent Enteral Nutr, 27, 51, 10.1177/0884533611431985